Project Grant HT94252510898
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $736K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $490,500.00 to the University of Texas MD Anderson Cancer Center in Houston, TX. The funds will support a 3-year research project titled "COMBINING TROP2-DIRECTED CAR-NK CELLS WITH HIF2A INHIBITION FOR THE IMMUNOTHERAPY OF PANCREATIC CANCER". The research aims to develop and evaluate a novel immunotherapy approach combining chimeric antigen receptor...
- This $613,125 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of EGFRXHER3 bispecific CAR-T cells for targeting EGFR tyrosine kinase inhibitor drug-tolerant persister cells. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period of 3 years from February 2025 to January 2028. The research aims to advance innovative therapeutic approaches...
- This Project Grant award, valued at $590,625.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Los Angeles (UCLA) for a pilot study on dual immunotherapy in combination with chemotherapy for patients with pancreatic adenocarcinoma. The award, with a period of performance from September 1, 2025 to August 31, 2028, will support research to investigate the immune mechanisms of resistance to this...
- This Project Grant award for $536,186.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct research on APOBEC3A and its role in tumor evolution and intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC). The award will fund this research project over a 3-year period from Sep 30, 2023 to Sep 29, 2026. As...
- The Project Grant award of $1,387,727.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma" research project conducted by the Sloan-Kettering Institute for Cancer Research in New York, NY. The award period runs from September 1, 2025 to August 31, 2029. The research aims to advance the scientific understanding and develop innovative diagnostic...
- This $118,722 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to develop a novel immunotherapy for pancreatic cancer. The grant funding will be used by Emory University to engineer CD4+ T cells expressing high levels of the enzyme CD26 and equip them with a chimeric antigen receptor (CAR) targeting mesothelin, a protein expressed on pancreatic tumor cells. The research aims to harness the favorable properties of CD26+ T cells to...
- This federal Project Grant award of $1,348,314.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The funding supports a research project titled "BUILDING T-CELL PRODUCTS IN NF1-ASSOCIATED MPNST THROUGH ANTIGEN DISCOVERY AND EPIGENOME TARGETING". The project aims to conduct advanced biomedical research to transform healthcare for military service members,...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at the University of Texas MD Anderson Cancer Center to investigate a novel therapeutic strategy for overcoming immunotherapy resistance in clear cell renal cell carcinoma (cCRCC). The $817,496 award, effective from September 1, 2025 to August 31, 2028, is focused on targeting the PRMT3-IGF2BP1 axis to understand epitranscriptomic reprogramming and...
- This Project Grant award of $718,858.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center in Houston, TX to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The project will run from February 15, 2025 to February 14, 2028, with the goal of advancing scientific understanding and potential clinical applications in this...
- This Project Grant award of $405,000.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research by Panorama Research Incorporated, a for-profit biotech company in Sunnyvale, CA. The research aims to develop novel immunotherapies that target dual cancer-specific antigens for the treatment of advanced ovarian cancer. The 2-year project will leverage Panorama's expertise in areas like antibody humanization, cell line...